利福布汀被脓肿分枝杆菌 Arr. 失活
Rifabutin Is Inactivated by Mycobacterium abscessus Arr.
机构信息
Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
National Center for Mycobacteria, University of Zurich, Zurich, Switzerland.
出版信息
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02215-20.
Abstract
exhibits Arr (ADP-ribosyltransferase)-dependent rifampin resistance. In apparent contrast, rifabutin (RBT) has demonstrated promising activity in infection models, implying that RBT might not be inactivated by Arr. RBT susceptibility testing of revealed a strongly decreased MIC. Our findings suggest that the efficacy of RBT might be enhanced by rendering RBT resilient to Arr-dependent modification or by blocking Arr activity.
摘要
表现出 Arr（ADP-ribosyltransferase）依赖性利福平耐药性。相比之下，利福布丁（RBT）在 感染模型中显示出有前景的活性，这意味着 Arr 可能不会使 RBT 失活。对 进行的 RBT 药敏试验显示 MIC 明显降低。我们的研究结果表明，通过使 RBT 能够抵抗 Arr 依赖性修饰或通过阻断 Arr 活性，RBT 的疗效可能会增强。
相似文献
1
Rifabutin Is Inactivated by Mycobacterium abscessus Arr.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02215-20.
2
Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
J Antimicrob Chemother. 2017 Feb;72(2):376-384. doi: 10.1093/jac/dkw466. Epub 2016 Dec 20.
3
Mycobacterium abscessus HelR interacts with RNA polymerase to confer intrinsic rifamycin resistance.
Mol Cell. 2022 Sep 1;82(17):3166-3177.e5. doi: 10.1016/j.molcel.2022.06.034. Epub 2022 Jul 28.
4
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
5
Rifabutin Is Active against Mycobacterium abscessus Complex.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
6
Rifabutin Is Active against Mycobacterium abscessus in Mice.
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
7
In vitro activity of rifabutin against Mycobacterium abscessus, clinical isolates.
Clin Exp Pharmacol Physiol. 2022 Jul;49(7):767-775. doi: 10.1111/1440-1681.13651. Epub 2022 Jun 5.
8
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.
9
and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against .
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01915-18. Print 2019 Apr.
10
Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00283-18. Print 2018 Aug.
引用本文的文献
1
Toward better cures for lung disease.
Clin Microbiol Rev. 2024 Dec 10;37(4):e0008023. doi: 10.1128/cmr.00080-23. Epub 2024 Oct 3.
2
Loss of allosteric regulation in α-isopropylmalate synthase identified as an antimicrobial resistance mechanism.
NPJ Antimicrob Resist. 2023;1(1):7. doi: 10.1038/s44259-023-00005-4. Epub 2023 Jul 3.
3
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
4
Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in abscessus.
Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2314101120. doi: 10.1073/pnas.2314101120. Epub 2024 Jan 2.
5
Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.
Microbiol Spectr. 2023 Sep 8;11(5):e0190023. doi: 10.1128/spectrum.01900-23.
6
ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant in caseum surrogate.
Antimicrob Agents Chemother. 2023 Sep 19;67(9):e0038123. doi: 10.1128/aac.00381-23. Epub 2023 Jul 26.
7
C25-modified rifamycin derivatives with improved activity against .
PNAS Nexus. 2022 Aug 9;1(4):pgac130. doi: 10.1093/pnasnexus/pgac130. eCollection 2022 Sep.
8
Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.
Angew Chem Int Ed Engl. 2022 Nov 7;61(45):e202211498. doi: 10.1002/anie.202211498. Epub 2022 Oct 12.
9
Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein.
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0086421. doi: 10.1128/AAC.00864-21. Epub 2021 Oct 4.
10
Current Molecular Therapeutic Agents and Drug Candidates for .
Front Pharmacol. 2021 Aug 30;12:724725. doi: 10.3389/fphar.2021.724725. eCollection 2021.
本文引用的文献
1
A Simplified and Efficient Method for Himar-1 Transposon Sequencing in Bacteria, Demonstrated by Creation and Analysis of a Saturated Transposon-Mutant Library in Mycobacterium abscessus.
mSystems. 2020 Oct 20;5(5):e00976-20. doi: 10.1128/mSystems.00976-20.
2
Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00363-20.
3
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.
Nat Rev Microbiol. 2020 Jul;18(7):392-407. doi: 10.1038/s41579-020-0331-1. Epub 2020 Feb 21.
4
Rifabutin Is Active against Mycobacterium abscessus in Mice.
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
5
Identification of novel scaffolds targeting Mycobacterium tuberculosis.
J Mol Med (Berl). 2019 Nov;97(11):1601-1613. doi: 10.1007/s00109-019-01840-7. Epub 2019 Nov 14.
6
Extremely Low Hit Rate in a Diverse Chemical Drug Screen Targeting Mycobacterium abscessus.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01008-19. Print 2019 Nov.
7
Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2112-2115. doi: 10.1016/j.bmcl.2019.07.001. Epub 2019 Jul 2.
8
New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00733-19. Print 2019 Sep.
9
Repositioning rifamycins for Mycobacterium abscessus lung disease.
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
10
The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Drug Resistance.
Front Microbiol. 2018 Sep 12;9:2179. doi: 10.3389/fmicb.2018.02179. eCollection 2018.
Zotero 插件